The Role of Gonadotropin-Releasing Hormone Antagonists for the Treatment of Benign Prostatic Hyperplasia

Reviews in Urology

Herbert Lepor¹ 

[1] Department of Urology, New York University School of Medicine, New York, NY

关键词: Benign prostatic hyperplasia;    Alpha-blockers;    Lower urinary tract symptoms;    5-α reductase inhibitors;    LH-RH antagonists;    Cetrorelix;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

Medical therapy is the preferred first-line approach in the management of lower urinary tract symptoms in men with benign prostatic hyperplasia. The magnitude of the improvement in lower urinary tract symptoms observed in response to combination therapy (α-blocker plus 5-α reductase inhibitors) does not approach that achieved with prostatectomy. Various drugs have been under consideration, including BXL628, lonidamine, and phosphodiesterase inhibitors, all of which have had unacceptable side effects. The gonadotropin-releasing hormone antagonist cetrorelix is associated with dose-dependent symptom improvement and reduction of prostate volume. Elucidating the mechanism for cetrorelix-mediated improvement in lower urinary tract symptoms will likely contribute to unraveling the pathophysiology of lower urinary tract symptoms in men.

【 授权许可】

Unknown